期刊
OTOLOGY & NEUROTOLOGY
卷 37, 期 8, 页码 E286-E294出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MAO.0000000000001134
关键词
Audiology; Auditory; Clinical research; OAE; Otoacoustic emissions
资金
- Department of Veterans Affairs (VA), Office of Rehabilitation Research and Development Service (RRD) [C0239R]
- Department of Defense [W81XWH-15-1-0103]
- Knowles Hearing Center Collaborative Grant
- OHSU-PSU School of Public Health
- Mimosa Acoustics
The purpose of this report is to provide guidance on the use of otoacoustic emissions (OAEs) as a clinical trial outcome measure for pharmaceutical interventions developed to prevent acquired hearing loss secondary to cochlear insult. OAEs are a rapid, noninvasive measure that can be used to monitor cochlear outer hair cell function. Serial monitoring of OAEs is most clearly established for use in hearing conservation and ototoxicity monitoring programs in which they exhibit more frequent and earlier changes compared with pure-tone audiometry. They also show promise in recent human trials of otoprotectants. Questions remain, however, concerning the most appropriate OAE protocols to use and what constitutes a significant OAE response change. Measurement system capabilities are expanding and test efficacy will vary across locations and patient populations. Yet, standardizing minimal measurement criteria and reporting of results is needed including documentation of test-retest variability so that useful comparisons can be made across trials. It is also clear that protocols must be theoretically sound based on known patterns of damage, generate valid results in most individuals tested, be accurate, repeatable, and involve minimal time. Based on the potential value added, OAEs should be included in clinical trials when measurement conditions and time permit.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据